Join IAG and WPD Pharmaceuticals’ Experts to Discuss the Potential of Advanced Imaging to Show Early Treatment Effects of Berubicin in Brain Cancer
Join Mariusz Olejniczak, CEO of WDP Pharmaceuticals, and Diana Dupont-Roettger, Chief Scientific Alliance Officer of IAG, during a live webinar to discuss how advanced imaging can show early treatment effects in brain cancer.
Bringing a novel glioblastoma multiforme (‘GBM’) therapy to the market requires a robust clinical trial that will assess the effectiveness of the potential treatment. The design and delivery of such trials is a challenge.
If you are interested in a replay, please reach out to email@example.com
About the Webinar:
WPD Pharmaceuticals (‘WPD’) is a biotechnology research and development company focused on developing drug candidates involved in targeted therapy for brain cancers. Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer. www.wpdpharmaceuticals.com
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin